Abnormal interactions between misfolded mutant and wild-type (WT) proinsulin in the endoplasmic reticulum (ER) drive the molecular pathogenesis of Mutant-INS-gene induced Diabetes of Youth (MIDY). How these abnormal interactions are initiated remains unknown. Normally, proinsulin-WT dimerizes in the ER. Here, we suggest that the normal proinsulin-proinsulin contact surface, involving the B-chain, contributes to dominant-negative effects of misfolded MIDY mutants. Specifically, we find that proinsulin Tyr-B16, which is a key residue in normal proinsulin dimerization, helps confer dominant-negative behavior of MIDY mutant proinsulin-C(A7)Y. Substitutions of Tyr-B16 with ether Ala, Asp, or Pro in proinsulin-C(A7)Y each decrease the abnormal interactions between the MIDY mutant and proinsulin-WT, rescuing proinsulin-WT export, limiting ER stress, and increasing insulin production in b-cells and human islets.
Introduction
Proinsulin misfolding, endoplasmic reticulum (ER) stress, and decreased b-cell mass are key features of b-cell failure and diabetes in the autosomal-dominant diabetes known as Mutant-INS-gene induced Diabetes of Youth (MIDY) (1) (2) (3) . All MIDY patients carry a mutation in one of two INS alleles (3) (4) (5) (6) , although, in principle, only one normal INS allele should be sufficient to maintain normoglycemia (7) . The underlying mechanism of MIDY is thought to involve abnormal interactions of misfolded mutant proinsulin with bystander proinsulin-WT in the ER, impairing the ER export of proinsulin-WT and decreasing production of bioactive mature insulin (8) (9) (10) . However, to date, how these interactions are initiated remains largely unknown. Interestingly, the clinical spectrum of MIDY ranges from neonatal-onset severe insulin deficient diabetes to relatively lateonset mild diabetes (1, 2) , suggesting that different proinsulin mutants may behave differently in their folding processes, as well as their ability to interact and obstruct bystander proinsulin-WT in the ER.
In this study, we report that a proline (Pro) substitution for tyrosine residue at the 16 th position of the proinsulin B chain (Tyr-B16) [i.e., proinsulin-Y(B16)P] results in dramatic proinsulin misfolding in the ER, and yet is unable to interact with bystander proinsulin-WT in the ER, and is unable to impair the ER export of proinsulin-WT or to block its ability to form mature insulin. Interestingly, Y(B16)P disrupts the main α-helix in the proinsulin B-domain. Normally, proinsulin uses this B-domain α-helix in order to homodimerize in the ER (11) . Thus, we hypothesize that cross-dimerization between that impairs the intracellular transport of proinsulin-WT, resulting in insulin deficiency that leads to diabetes (12) .
Structural evidence strongly implicates Tyr-B16 as a key residue for normal proinsulin dimerization (13) . With this in mind, we have mutagenized this residue to either aspartic acid [Y(B16D)] Asp) or alanine [Y(B16)A]; both substitutions were entirely innocuous when introduced into proinsulin-WT. However, when these substitutions were introduced into a MIDY causing Akita proinsulin-C(A7)Y, they both could function as an intra-allelic suppressor, blocking abnormal interactions with proinsulin-WT; alleviating dominant-negative behavior on proinsulin-WT intracellular trafficking; and increasing insulin production in pancreatic b-cell lines and human islets. This study provides insight that protecting the proinsulin-proinsulin contact surface might be a potential druggable target to limit abnormal proinsulin interactions and prevent/delay the development and progression of MIDY.
Results
In the ER, proinsulin dimerization (11, 14) involves nonpolar association of apposed Bchain residues 8-29 (encompassing the central B9-B19 α-helix), which continue to remain associated in mature insulin (15, 16) . The insulin crystal structure highlights that B16Y contributes more surface area to the dimerization interface than any other residue ( Fig. 1A, B ), and a substitution of this residue yields a high potency monomeric insulin (13) . We therefore engineered both two-chain and single-chain insulin derivatives bearing the Y(B16)D substitution, both of which showed impaired dimerization in dilute solution as judged by size exclusion chromatography and 1D NMR spectroscopy, respectively ( Fig. S1A, B ). To determine the role of TyrB16 in proinsulin folding and dimerization in the ER, we expressed proinsulin-Y(B16)D and Y(B16)A in 293T cells, and demonstrated these substitutions affect neither proinsulin ER oxidative folding ( We hypothesize that the proinsulin-proinsulin contact surface initiates the attack by misfolded MIDY proinsulin mutants on co-expressed proinsulin-WT. We therefore decided to explore the role of proinsulin-Y(B16) in the interactions between the MIDYcausing "Akita" proinsulin-C(A7)Y and proinsulin-WT. In 293 cells we co-expressed untagged human proinsulin-WT with Myc-tagged human proinsulin-WT or C(A7)Y [Myc-PI-C(A7)Y] with or without Y(B16)D substitution ( Fig. 2A , lanes 4-6 and 4'-6').
By nonreducing SDS-PAGE and anti-proinsulin immunoblotting, the overexpression of either untagged proinsulin-WT (PI-WT) or Myc-tagged proinsulin-WT (Myc-PI-WT) resulted in detectable formation of homotypic disulfide-linked complexes ( Fig. 2A , lanes 2 and 3). Recent evidence indicates that Akita proinsulin is similarly predisposed to form a ladder of aberrant disulfide-linked complexes even at low expression levels (17) (18) (19) , and Akita proinsulin can heterotypically co-recruit proinsulin-WT into these aberrant complexes (10) . Next, we asked whether the decreased interaction of MIDY proinsulin-C(A7)Y with proinsulin-WT could also alleviate the dominant-negative effect on proinsulin-WT secretion. We first examined folding and secretion of proinsulin-C(A7)Y with or without B16 substitutions, and found that introduction of Asp (D), Ala (A), or Pro (P) had no effect on the impaired disulfide maturation of proinsulin-C(A7)Y and did not rescue secretion of the MIDY mutant (which was retained intracellularly; Fig. 3A-B ). We then checked whether B16 substitutions could limit the effect of proinsulin-C(A7)Y on bystander proinsulin-WT. We co-expressed mouse proinsulin-C(A7)Y ± Y(B16)D or Y(B16)P substitutions with human proinsulin-WT in HEK293T cells. We used a species-specific immunoassay to follow secretion of the co-expressed human proinsulin-WT in the presence of mutant proinsulin. Indeed, the expression of mouse proinsulin-C(A7)Y blocked the secretion of proinsulin-WT by ~70% ( Fig. 3C ), consistent with previous reports (9, 10, 20, 21) . However, the Y(B16)D substitution [or Y(B16)P] functioned as an intra-allelic suppressor of the dominant-negative effect of proinsulin-C(A7)Y on the secretion of co-expressed proinsulin-WT ( Fig. 3C ).
These immunoassay results were then confirmed using pulse-chase experiments. Once again, proinsulin-Y(B16)A and proinsulin-Y(B16)D were secreted normally, in parallel with the secretion of co-expressed proinsulin-WT ( Fig. 3D, lanes 15 or 21) . Further, both misfolded mutants proinsulin-C(A7)Y and proinsulin-Y(B16)P were fully blocked in their secretion; however, the Akita proinsulin-C(A7)Y conferred a clear dominantnegative effect on co-expressed proinsulin-WT that was not apparent for proinsulin-Y(B16)P (Fig. 3D, lanes 12 vs 18) , indicating that not all misfolded proinsulin mutants have the ability to block secretion of bystander proinsulin-WT. Moreover, we found that To further investigate effect of B16 substitutions on endogenous proinsulin in b-cells, we transfected GFP-tagged proinsulin-WT or mutants, and used three independent approaches to examine trans-dominant effects. First, using confocal immunofluorescence, we found that while GFP-proinsulin-WT and Y(B16)D showed a punctate insulin secretory granule pattern, proinsulin-C(A7)Y appeared in a typical ER pattern and caused a profound loss of endogenous insulin ( 4D ). Finally, the enhanced ER export of proinsulin-WT correlated with decreased ER stress in b-cells co-expressing proinsulin-C(A7)Y versus C(A7)Y/Y(B16)D, as measured in a transcriptional BiP promoter reporter assay (Fig. 4D ). Taken together, these results strongly suggest that Tyr(B16), which is a major component of the proinsulin-proinsulin interaction surface, is involved in the physical interaction between MIDY mutant proinsulin and proinsulin-WT, and this interaction is necessary for the mutant protein to block proinsulin-WT exit from the ER, impair insulin production, trigger ER stress, and promote the development of diabetes.
Discussion
To date, more than 50 insulin gene mutations have been reported to cause MIDY, an autosomal dominant form of diabetes (also known as MODY10) (8, 12) . More than 60% of the identified mutant alleles have been predicted or experimentally confirmed to impair oxidative folding of proinsulin in the ER (1, 22) . Importantly, these misfolded MIDY mutants not only fail to exit from the ER, but also physically attack co-expressed proinsulin-WT, impairing the folding and ER export of co-expressed proinsulin-WT, decreasing insulin production, and initiating insulin-deficient diabetes (12, 20, 23) .
Heretofore, the molecular mechanism underlying these dominant-negative effects have been completely unknown. As the proinsulin-proinsulin contact surface might possibly engage even before completion of the folding of individual proinsulin monomers, the present work focuses attention on this surface as a possible site initiating the attack of misfolded mutant proinsulin onto bystander proinsulin in the ER.
In this study, we have found at least two substitutions of the key Tyr-B16 residue that have no observable impact on proinsulin monomer folding or ER export, but can limit proinsulin-proinsulin contact and thereby can decrease abnormal interactions and alleviate trans-dominant effects of observed in MIDY. It is interesting to note that among the roughly 30 known proinsulin sites/residues that trigger MIDY, none has yet been described that introduces a charged or highly polar residue into the B9-B19 α-helix. We postulate that such substitutions may be relatively ineffective in propagating misfolding onto bystander proinsulin-WT molecules. This hypothesis is supported by data from the proinsulin-Y(B16)P mutant, which disrupts the B9-B19 α-helix to cause severe proinsulin misfolding and ER retention (Fig. 1C-FF) but cannot impose a dominant-negative effect on bystander proinsulin-WT (Fig. 3D) . These data support the notion that proinsulinproinsulin contact is an early folding event and initiates the trans-dominant effects of MIDY mutants.
Increasing evidence indicates that proinsulin misfolding and ER stress not only are the molecular basis of MIDY, but may also play an important role in the development and progression of type 1 and type 2 diabetes (2, (24) (25) (26) (27) . Increased proinsulin misfolding has been recently reported in b-cells with either defects in the ER folding environment (28) (29) (30) , or defective ER export machinery (18) , or proinsulin oversynthesis due to insulin resistance in rodent and human type 2 diabetes islets (19) . These data suggest that proinsulin misfolding is an early event in the progression to type 2 diabetes. As the most abundant protein synthesized in b-cells, proinsulin is predisposed to misfold (12, 20, 31) from which it may propagate this misfolding onto bystander proinsulin (8) (9) (10) . This becomes an important driving force for b-cell ER stress and insulin deficiency (29, (32) (33) (34) . The data in this report provide the first evidence pointing to the idea that initial proinsulin-proinsulin B-chain contact may be a site worth targeting, to block crossdimerization of misfolded proinsulin with proinsulin bystanders, enhance insulin production, and offer a new approach to preventing b-cell insulin deficiency and diabetes ( Fig. 5 ). The secretion efficiency of un-tagged PI-WT in the presence or absence of Myc-PI-WT or mutants were analyzed under reducing conditions, followed by phosphorimaging. proinsulin dimerization surface of the mutant can abnormally interact with that of the coexpressed bystander proinsulin-WT, which impairs the folding and ER export of proinsulin-WT. Proinsulin TyrB16 plays a key role in proinsulin dimerization in the ER.
Figure legends

B.
Protecting the proinsulin dimerization surface may sever as a potential theropeutic target to limit trans-dominant effects of misfolded mutant proinsulin, alleviating ER stress and b-cell failure. Quantification of these data demonstrate that the Asp B16 analogue forms at least three times more monomer than the Tyr B16 analogue. B. Single-chain Tyr B16 -DesDi insulin analogue or Asp B16 -DesDi insulin analogue were synthesized (49 residues, see Methods).
Supplementary Figure Legends
The aromatic region from 1D 1 H NMR spectra at 700 MHz and 25 o C reveal resonance broadening due to self-association of Tyr B16 -DesDi single-chain insulin analog (below), which is notably mitigated in the Asp B16 -DesDi single-chain insulin analog (above). 
